118
Participants
Start Date
November 30, 2009
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Cilostazol, Probucol / placebo of probucol
An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
Severance Hospital, Yonsei University Health System, Seoul
Collaborators (1)
Korea Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Yonsei University
OTHER